Contract Manufacturing, General

BioVectra will open its new microbial fermentation and complex chemistry site, including the capability to handle high-potency APIs, by the end of 2017.

GE Healthcare continues to ramp up its offerings in the bioprocessing space with the purchase of Asymptote and a continued partnership with Zenith Technologies.

AGC adds second biopharma contract manufacturer with acquisition of CMC Biologics.

Technology advances enable contract service providers to keep pace with the demands of existing and emerging biologic-based therapies.

Contract service providers debate the pros and cons of consolidation, accelerated drug approvals, regulatory issues, and the impact of new therapies.

Biopharmaceutical contractors continue to invest in development, facility upgrades, technological advancement, and mergers and acquisitions.

Advances in single-use systems, consumables, and continuous manufacturing show steady progress.

Pfizer announced the launch of Pfizer CentreOne, a CMO formed by the combination of Pfizer CentreSource and Hospira One 2 One.

Grand River Aseptic Manufacturing expands disposable technology capabilities at aseptic facility.

Under the terms of the agreement, Xellia will acquire substantial parts of the Ben Venue site, including four sterile injectable manufacturing plants, which are not currently operational.

*This article is an opinion piece and does not necessarily represent the views of BioPharm International.

CMC Biologics and River Vision Development announce manufacturing agreement for RV001, a monoclonal antibody to treat Grave’s orbitopathy.

The $19.7 million contract will assist Emergent with the development of cGMP lots of three Ebola mAbs.

The new project will increase fill/finish manufacturing capacity for select products on FDA’s Drug Shortage Index.

Jim Miller, President of PharmSource, speaks with BioPharm International.

Jim Miller, President of PharmSource, spoke with BioPharm International about working with CMOs and CDMOs.

Rentschler Biotechnologie launches 2000-L single-use bioreactor and announces additional expansion.

Patheon cites expanded API services with acquisition of IRIX Pharmaceuticals.

Biomanufacturing capacity expansion uses modular cleanroom design and single-use technologies.

Outsourcing is taking on a greater role in the biopharmaceutical manufacturing industry.

European CDMOs want into the US market, but entry options are limited.

The trend of exits from the CMO industry looks to be gaining momentum.

With budgets growing, clients see CMOs' costs as less crucial.

Evolving clinical trial research services give biopharmaceutical companies options for full- and functional-services.

The CMO industry's value proposition is limiting its market penetration.

Outsourcing activity remains strong and unlikely to abate, especially in more traditional areas.

Changes in company ownership shake up the CMO industry.

Ongoing changes create new opportunities for CROs and CMOs.

Are strategic partnerships in clinical research a model for CMC services?

Approvals of new drugs are on an upward swing, but only a few CMOs are benefiting.